{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"PCSK9 Inhibitors Show Similar Efficacy in Diabetics as in Other High-Risk Groups - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"E4FBcf4w8g\"><a href=\"https:\/\/themedicalxchange.com\/en\/2015\/11\/16\/american-heart-association-aha-scientific-sessio-6\/\">PCSK9 Inhibitors Show Similar Efficacy in Diabetics as in Other High-Risk Groups<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2015\/11\/16\/american-heart-association-aha-scientific-sessio-6\/embed\/#?secret=E4FBcf4w8g\" width=\"600\" height=\"338\" title=\"&#8220;PCSK9 Inhibitors Show Similar Efficacy in Diabetics as in Other High-Risk Groups&#8221; &#8212; The Medical Xchange\" data-secret=\"E4FBcf4w8g\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2015\/11\/2351_AHA_2015_EN_Fig_1.png","thumbnail_width":960,"thumbnail_height":720,"description":"Orlando \u2013 PCSK9 inhibitors offer the same magnitude of low-density lipoprotein cholesterol (LDL-C) reduction in patients with diabetes mellitus as in other high-risk groups, according to a series of studies presented at the AHA Scientific Sessions. In this series, there was also no evidence that PCSK9 inhibition imposes any adverse influence on glucose metabolism. This latter finding is important in the context of new data that strengthen the modest but measurable association of statins with new-onset diabetes."}